Commercial shipments of the product has commenced. Ramipril had annual sales of $920 million for the twelve months ended December 2007, based on IMS Health sales data.
Lupin's Ramapril capsules are the AB-rated generic equivalent of King Pharmaceutical's Altace capsules, indicated for the treatment of hypertension.
On June 5, in an effort to restrict Lupin's launch, King filed a motion for a temporary restraining order (TRO) and preliminary injunction against Lupin Pharmaceuticals.
The hearing occurred on June 10 and King's motion was denied, it said.
